Cargando...
Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies
RAF kinase inhibitors are clinically active in patients with BRAF (V600E) mutant melanoma. However, rarely do tumors regress completely, with the majority of responses being short-lived. This is partially mediated through the loss of negative feedback loops after MAPK inhibition and reactivation of...
Gardado en:
| Publicado en: | J Exp Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Rockefeller University Press
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6028519/ https://ncbi.nlm.nih.gov/pubmed/29880484 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20171960 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|